Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Core Insights - Propanc Biopharma, Inc. is advancing its biopharmaceutical development focused on novel treatments for recurrent and metastatic cancer, with significant updates on corporate progress and financial results as of December 31, 2025 [1] Corporate and R&D Highlights - The company has filed four provisional patent applications to enhance global protection for its breakthrough proenzyme formulations, which is expected to increase its IP portfolio from approximately 90 to over 200 patents [2] - Key findings regarding the impact of proenzymes on pancreatic ductal adenocarcinoma fibroblasts were published in a peer-reviewed journal, highlighting the potential of PRP as a disruptor of the tumor microenvironment [3] Financial Updates - Propanc has entered into a private placement agreement for up to $100 million to accelerate clinical development, receiving an initial investment of $1 million [4] - The company reported total assets of $15.11 million and reduced total liabilities by $2.07 million, with convertible notes decreasing to $55,000 from $538,000 [8] Management Commentary - The CEO expressed satisfaction with the advancements in R&D programs, particularly the lead asset PRP, which is being prepared for a Phase 1b, First-In-Human study in advanced cancer patients [7] Financial Performance - For the quarter ended December 31, 2025, the company reported a net loss of $3,091,394, with total operating expenses of $3,654,734 [15] - The basic and diluted net loss per share was reported at $0.30 for the three months ended December 31, 2025 [16]